Bromide

Bromide

SCHEMBL1087062

C[N+]1(CCOc2ccccc2)CCC(O)CC1.[Br-]

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 7/20 0.49
CHRM2 known ✓ P08172 4/20 0.49
ACHE known ✓ P22303 2/20 0.47
CHRNB2 P17787 5/20 0.51
CHRNB4 P30926 5/20 0.51
CHRNA3 P32297 5/20 0.51
CHRNA7 P36544 5/20 0.51
CHRNA4 P43681 5/20 0.51
CHRNA10 Q9GZZ6 4/20 0.51
CHRNA9 Q9UGM1 4/20 0.51
SLC18A3 Q16572 2/20 0.47
TAAR1 Q96RJ0 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RECQL P46063 1/20 0.41
KCNA3 P22001 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12633420 0.84 CHRNB2 (0.54) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL12633413 0.84 CHRNB2 (0.54) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL12633507 0.82 CHRNB2 (0.51) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL12633477 0.77 CHRM3 (0.49) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Bromide SCHEMBL1872734 0.75 CHRM3 (0.62) CHRM3CHRM2
Bromide SCHEMBL1872736 0.75 CHRM3 (0.62) CHRM3CHRM2
SCHEMBL12633506 0.75 CHRM3 (0.47) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL14448113 0.74 KCNH2 (0.57) CHRNA7CHRM3CHRM2ACHESLC18A3
Bromide SCHEMBL1087864 0.74 CHRM2 (0.48) CHRM3CHRM2SLC18A3ALDH1A1
SCHEMBL12633520 0.74 CHRNB2 (0.52) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153669-B2 Quaternary ammonium salts as M3 antagonists NOVARTIS AG (CH) 2012-04-10 US disclosed
EP-1831208-B1 QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS NOVARTIS AG (CH) 2011-08-24 EP disclosed
US-20090227590-A1 QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS NOVARTIS AG (CH) 2009-09-10 US disclosed
EP-1831208-A1 QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS Novartis AG (CH) 2007-09-12 EP disclosed
WO-2006066929-A1 QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS NOVARTIS AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227590-A1 QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS CHRM2, CHRM1, CHRM3 CHRM3 3/4885CHRM2 1/4885ACHE 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.